Dendritic Cell Vaccine (ADCV01)

The Dendritic Cell (DC) vaccine is formed by co-culture of DC cells extracted by in vitro apheresis and tumor cells removed from surgery.  Together with both the DC cells and the tumor cells, we manufacture to produce the DC vaccine (ADCV01) with tumor antigen.  Furthermore, the vaccine is injected back into the cancer patients' body and helped in vivo training of T cells such that immune cells are capable of attacking, engulfing and dissolving the cancer cells with accuracy and effectiveness, and to destroy and to suppress tumor growth.

Advantages of ADCV01

■   Highly specific separation on different types of cancer cells.

■   Special technology with tumor cell antigen specificity.

■   Low body rejection rate and side effects.